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It was recently demonstrated that embryonic
glucagon-producing cells in the pancreas can
regenerate and convert into insulin-producing
b-like cells through the constitutive/ectopic expres-
sion of the Pax4 gene. However, whether a cells in
adult mice display the same plasticity is unknown.
Similarly, the mechanisms underlying such reprog-
ramming remain unclear. We now demonstrate
that the misexpression of Pax4 in glucagon+ cells
age-independently induces their conversion into
b-like cells and their glucagon shortage-mediated
replacement, resulting in islet hypertrophy and in
an unexpected islet neogenesis. Combining several
lineage-tracing approaches, we show that, upon
Pax4-mediated a-to-b-like cell conversion, pancre-
atic duct-lining precursor cells are continuously
mobilized, re-express the developmental gene
Ngn3, and successively adopt a glucagon+ and a
b-like cell identity through a mechanism involving
the reawakening of the epithelial-to-mesenchymal
transition. Importantly, these processes can repeat-
edly regenerate the whole b cell mass and thereby
reverse several rounds of toxin-induced diabetes,86 Developmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc.providing perspectives to design therapeutic regen-
erative strategies.
INTRODUCTION
The endocrine pancreas is organized into micro-organs termed
islets of Langerhans comprising a, b, d, ε, and pancreatic poly-
peptide (PP) cells secreting glucagon, insulin, somatostatin,
ghrelin, and PP, respectively. Both types I and II diabetes condi-
tions may ultimately result in pancreatic b cell loss and chronic
hyperglycemia. Although current therapies provide a measure
of control of the glycemia, treated diabetic patients still display
a dramatically shortened life expectancy as compared to their
healthy counterparts (Diabetes in the UK 2010: Key statistics
on diabetes online, http://www.diabetes.org.uk/Documents/
Reports/Diabetes_in_the_UK_2010.pdf). In this context, deci-
phering the mechanisms underlying b cell genesis/regeneration
may uncover avenues toward alternative therapies. Thus, it
was previously demonstrated that, during pancreasmorphogen-
esis, the activation of a transcription factor network successively
specifies progenitor cells toward the pancreatic, endocrine, and
ultimately islet cell fates (Habener et al., 2005). Hence, Pdx1
determines the pancreatic epithelium (Ahlgren et al., 1996;
Grapin-Botton et al., 2001; Jonsson et al., 1994; Offield et al.,
1996), whereas Ngn3 specifies the endocrine cell lineage
(Gradwohl et al., 2000; Gu et al., 2002; Johansson et al., 2007).
Developmental Cell
Reprogramming Adult Duct-Lining Cells into b CellsSubsequently, additional transcription factors were identified
through their involvement in islet cell lineage allocation. Among
these, Arx and Pax4 are instrumental for the specification toward
the a/PP and b/d cell fates, respectively (Collombat et al., 2003,
2005, 2007; Sosa-Pineda et al., 1997). Importantly, the forced
expression of Pax4 in embryonic glucagon+ cells was found to
induce their neogenesis and subsequent conversion into cells
displaying a b cell phenotype (Collombat et al., 2009). Interest-
ingly, the overexpression of Pax4 in b cells was also shown to
prevent their toxin-mediated loss (Hu He et al., 2011).
Although these findings allowed us to gain insight into the
regenerative potential and plasticity of embryonic/newborn
glucagon+ cells misexpressing Pax4, several issues of funda-
mental importance to type I diabetes remain hitherto unresolved:
(1) Do adult a cells that have been subjected to environmental
signaling, maturation, and aging retain the ability to be converted
into b-like cells upon Pax4 expression? (2) Could these
glucagon+ cells restore a functional beta-like cell mass after
beta cell ablation? (3) Is the number of precursor cells limited
and does it restrict b-like cell regeneration in aging mice? (4)
Can b cell neogenesis be controlled? (5) What are the mecha-
nisms underlying glucagon+ cell-mediated b-like cell neogene-
sis? To address these pivotal questions and thereby potentially
open avenues in the context of type I diabetes research, we
generated double-transgenic mice allowing the inducible,
ectopic, and reversible expression of Pax4 in glucagon-produc-
ing cells. Our results provide conclusive evidence that adult a
cells can also be converted into functional b-like cells at any
age upon Pax4 misexpression, and that a cycle of endocrine
cell/islet neogenesis is subsequently activated. Specifically, a
Ngn3-dependent reawakening of the epithelial-to-mesenchymal
transition in this adult context promotes duct-lining precursor
cells to adopt a glucagon+ cell identity and, subsequently, a
b-like cell phenotype, these being responsive to physiological
stimuli. Importantly, such controllable regeneration processes
allow for several cycles of replenishment of a complete b-like
cell mass that counters toxin-induced diabetes.
RESULTS
Adult a Cells Can Be Converted into b-like Cells upon
Pax4 Misexpression
Taking advantage of the Tet-ON system (Clontech Laboratories),
we generated two mouse lines using pronuclear injection of
recombinant transgenes (Figure S1 available online): Glu-rtTA
contained the rat glucagon promoter (Herrera et al., 1994)
upstream of the reverse tetracycline-dependent transactivator
and TetO-Pax4 included the Tet operator upstream of Pax4
cDNA. For each, four or more founder lines were generated. To
assess the specificity of the regulatory sequences and any
putative leakiness of transgene expression, Glu-rtTA mice
were crossed with the well-established TetO-b-gal mouse line
(Hennighausen et al., 1995). Pancreata of 4-week-old Glu-rtTA::
TetO-b-gal mice were assayed for b-galactosidase expression in
glucagon+ cells after 2 weeks of doxycycline (Dox) treatment
(Figure S2A). Transgene expression was found specifically
regulated by Glu-rtTA as b-galactosidase activity was detected
in 80%–90% of glucagon+ cells but not in any other cell type of
the pancreas.DeNext, Glu-rtTA::TetO-Pax4 animals were generated, treated
with Dox at 4 weeks of age, and assayed for Pax4 mRNA at
12 weeks of age. From here on, mice treated with doxycycline/
tamoxifen for x months will be referred to as xmDox+/xmTam+.
In all cases, untreated animals were found phenotypically
similar to their wild-type (WT) counterparts, and they will be
referred to as Dox/Tam or controls. Accordingly, wild-type
and Dox Glu-rtTA::TetO-Pax4 control mice displayed similarly
low levels of Pax4 mRNA (WT not shown and Figure S2B).
However, in pancreata of 2mDox+ Glu-rtTA::TetO-Pax4 mice,
the content in Pax4 transcripts was found considerably
increased from 2.6- to 27-fold as compared to control mice,
depending on the mouse line analyzed (and most likely on
the loci of integration of the transgenes). In the following
studies, the mouse line with 2.6-fold increase (line m2, Fig-
ure S2B) was used.
Bitransgenic Glu-rtTA::TetO-Pax4 mice were found to be
viable, fertile, and healthy. Their basal glycemia and life span
were within normal range, independent of Dox administration
(Table S1). Importantly, a thorough investigation of islet size in
Glu-rtTA::TetO-Pax4 mice of 1–11 months of age, treated with
Dox from 10 days up to 20 months, outlined a massive increase
in average islet size in all cases (Table S1; Figures 1A and 1B).
This hypertrophy was associated with a massive insulin+ cell
hyperplasia and was found not to depend on the age at Dox
administration (Table S1) but rather on its duration (Table S2).
For instance, 1.5-, 7-, or 11-month-old Glu-rtTA::TetO-Pax4
mice treated for 5 months with Dox all displayed an approximate
3.5-fold increase in average islet size compared to their
untreated counterparts (Table S2). As remarkable was the
2.7-fold increase in the overall islet number after only 10 days
of Dox administration (Table S2). Such neo-formed islets were
initially found relatively smaller in size (Figures S3A and S3B).
However, unlike the aforementioned continuous expansion of
islet size, the increase in islet number plateaued at approxi-
mately 2.8 times the numbers observed in controls (Table S2).
Islet hypertrophy/multiplication were further demonstrated by
means of optical projection tomography allowing visualization
of the entire pancreatic insulin+ cell content (Figures S3C–S3J;
Movie S1). Both head and tail of the pancreas were thereby
found to contain significantly more islets, a majority being
much larger than their control counterparts. Altogether, our
data indicate that the conditional misexpression of Pax4 in
a cells of any age results in a progressive islet hypertrophy
as well as in the generation of islets that are mainly composed
of insulin-expressing cells.
Phenotypic Analysis of Mice Conditionally
Misexpressing Pax4 in Adult a Cells
To determine whether the supplementary insulin-labeled cells
displayed a b cell signature, the expression of endocrine labels
was determined in pancreata of 4-, 6-, and 10-month-old
Glu-rtTA::TetO-Pax4 mice treated (or not) with Dox for
2–8 months (Figure 1 displaying 6-month-old 4mDox+ pan-
creata; data not shown). In all cases, insulin-expressing cells
uniformly expressed the bona fide b cell markers, including
Pdx1 (Figures 1C–1F), Nkx6.1 (Figures 1G–1J), Pax4 (Figures
1K–1N), PC1/PC3 (Figures 1O–1R), Glut-2 (Figures 1S–1V),
MafA (Figures S4A–S4D), and NeuroD1 (Figures S4E–S4H).velopmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc. 87
Figure 1. The Ectopic Expression of Pax4 in
Adult a Cells Induces an Insulin+ b-like Cell
Hyperplasia, Resulting in Hypertrophic Is-
lets and Also in Increased Islet Numbers
Representative pictures of immunohistochemical
analyses performed on pancreas sections of 4-,
6-, and 10-month-old WT/Dox (controls, A, C
and D, G and H, K and L, O and P, S and T) and on
age-/sex-matched Glu-rtTA::TetO-Pax4 mice
treated with Dox for 2, 4, or 8 months (Dox+
Glu-rtTA::TetO-Pax4, B, E and F, I and J, M and N,
Q and R, U and V). Represented 6-month-old
4mDox+ pancreas sections outline a dramatic
islet hypertrophy caused by an insulin+ cell
hyperplasia as well as a massive increase in islet
numbers (A and B). Importantly, insulin+ cells
uniformly express the bona fide b cell markers
Pdx1 (C–F), Nkx6.1 (G–J), Pax4 (K–N), PC1/3
(O–R), Glut2 (S–V), but also MafA, NeuroD1, and
Pax6 (Figure S4).
See also Tables S1 and S2, Figures S1–S4, and
Movie S1.
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(Figures S4I–S4L), but were predominantly negative for non-b
cell determinants, such as Arx, Brn4, glucagon, somatostatin,
and PP (Figures S4M–S4P; data not shown). To further ascer-
tain the identity of the insulin-producing cells observed in
Dox+ Glu-rtTA::TetO-Pax4 pancreata, electron microscopy
examination was combined with insulin detection by immuno-
gold labeling: a thorough analyses of more than 200 photo-
graphs per pancreas (n = 3) indicated that the ultrastructure
of insulin-producing cells found in Pax4-misexpressing88 Developmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc.pancreata was comparable to that of
WT b cells (Figures S3K–S3N).
In addition to the increased number of
islets and insulin+ cells, Dox+ Glu-rtTA::
TetO-Pax4 mice also showed aug-
mented contents of glucagon+ (Figures
2A–2C and S4Q), PP+ (Figures 2A, 2D,
and S4T), and somatostatin+ (Figures
2E, 2F, and S4S) cells (5.5, 2.7, or 14.6
times, respectively, in 7-month-old
5mDox+ Glu-rtTA::TetO-Pax4 animals
as compared to their Dox counter-
parts). Interestingly, these were not
found uniformly distributed within the
islet mantle but clustered at one pole of
the islet, adjacent to neighboring ducts
(Figures 2A–2F; Movie S2). Intriguingly,
and solely in Dox+ Glu-rtTA::TetO-Pax4
pancreata, ducts appeared consistently
surrounded by a cell-dense zone remi-
niscent of the mesenchyme phenotype
(Figure S5 and below). Altogether, these
data indicate that induced misexpres-
sion of Pax4 in a cells of any age results
in progressive b-like cell hyperplasia
and islet number increase. An atypical
location and augmented numbers ofnon-b cells are outlined near the ducts that are surrounded
by a cell-dense area.
Controlling Insulin-Producing Cell Regeneration
To determine whether the misexpression of Pax4 in adult
a cells and the resulting hyperplasia of insulin+ cells could be
controlled, 1.5-month-old controls or Glu-rtTA::TetO-Pax4
mice were administered (or not) with Dox for 1 month, Dox treat-
ment was subsequently continued (or not) for 3 additional
months. Quantitative analyses revealed a 2.1-fold increase in
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compared to their untreated counterparts (Figure 2G). Islet
size and insulin+ cell counts were found further increased in
4mDox+ mice (up to 6.3 times). Importantly, in 1mDox+ animals
examined 3 months after the interruption of Dox treatment, islets
did not continue to expand but they did remain enlarged as
compared to controls (2.3 times), indicating that the supple-
mentary insulin+ cells generated between 1.5 and 2.5 months
of age were maintained after the arrest of Pax4 misexpression
(Figure 2G). Interestingly, compared to controls, the amount of
Pax4 transcripts was 6.7-fold increased in 4mDox+ Glu-rtTA::
TetO-Pax4 mice and only 2.5-fold in 1mDox+ 3mDox mice
(Figure 2G). Concerning the latter, it is important to note that
Pax4 is normally expressed in adult b cells (Figures 1K and 1L;
Collombat et al., 2009; Lu et al., 2010): our results therefore
confirm an arrest of Pax4 misexpression, the 2.5-fold increase
in the Pax4 transcripts corresponding to the 2.3-fold augmenta-
tion in islet size (and thereby in Pax4+ insulin+ cells), as compared
to controls. The ectopic expression of Pax4 in adult glucagon+
cells and the subsequent islet hypertrophy can thus be tightly
controlled in this experimental model.
Mobilization of Ngn3-Re-expressing Duct-Lining
Precursor Cells to Adopt a Glucagon+ Cell Identity and,
Subsequently, a b Cell Phenotype
To determine the origin of newly formed insulin+ cells in Glu-
rtTA::TetO-Pax4 mice, further immunohistochemical analyses
and lineage-tracing experiments were undertaken. A small
number of insulin+/glucagon+ cells were consistently observed
(Figures 3A–3D), suggestive for a putative transitional stage
during b-like cell neogenesis. To validate this hypothesis, Glu-
rtTA::TetO-Pax4 mice were crossed with Glu-Cre::ROSA26-
b-gal animals allowing permanent labeling of 78% ± 8% of
cells that had ever expressed glucagon (Figures S6A–S6C
and S6G). Using a quantitative analysis of 4-month-old
2mDox+ Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-b-gal pan-
creata, insulin+ b-galactosidase+ cells (formerly glucagon+ cells)
were found to represent 45% ± 11% of the total insulin+ cell
count, that is 74% ± 9% of the calculated supplementary
insulin+ cell count (Figures 3E–3I and S6D–S6G). These results
suggest that adult glucagon+ cells can be regenerated and
converted into insulin+ b-like cells upon Pax4 induction. Indeed,
given the limitation in labeling of glucagon+ cells (78% ± 8%),
these data indicate that most of the supplementary insulin+ cells
derived from glucagon+ cells (74% ± 9% of these insulin+ cells
were found labeled).
In Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-b-gal animals,
glucagon+ cells are labeled independently of Pax4 misexpres-
sion. Therefore, since Pax4 is not induced in all glucagon+
cells, due to the inherent imperfection of these transgenic
systems, it could have a paracrine effect on Pax4
b-galactosidase+ glucagon+ cells and induce their conversion
into b-galactosidase+ b-like cells. To exclude this possibility,
Glu-rtTA::TetO-Pax4 mice were also crossed to TetO-Cre::
ROSA26-b-gal animals, the resulting quadruple transgenics
allowing the sole labeling of glucagon+ cells having misex-
pressed Pax4. Two-month-old animals were also treated with
Dox for 2 months (or 4 months), and results similar to that found
in Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-b-gal mice wereDeobtained with a labeling of 74%–76% of neogenerated b-like
cells (Figure S6G). Thus, the proportion of b-galactosidase+
b-like cells was found unchanged acrossmodels or with different
induction times, indicating that Pax4 does not have a paracrine
activity on Pax4 glucagon+ cells.
Of further interest was the detection of very few cells simulta-
neously expressing endocrine hormones and the duct-specific
biomarker osteopontin in islets and/or adjacent to ducts (Figures
3J–3L). To examine a putative ductal ontogeny of these cells,
HNF1b-CreER mice (Solar et al., 2009), allowing the labeling
and tracing of 40% ± 8% of HNF1b+ duct cells (Figures S6H–
S6K), were crossed with Glu-rtTA::TetO-Pax4::ROSA26-b-gal
mice. When Glu-rtTA::TetO-Pax4::HNF1b-CreER::ROSA26-
b-gal micewere treated with Dox+Tam,42%±8%of duct cells
showed b-galactosidase activity (Figures 3M–3U and S6H–S6K).
Importantly, 38% ± 7% of neogenerated (or newly formed)
endocrine cells were found to be b-galactosidase+, supporting
the concept that a majority of these endocrine cells passed
through a HNF1b+ transitional phase. Thus, tracing of different
cell lineages provide conclusive evidence that the ectopic
expression of Pax4 in adult a cells can stimulate a subset of
HNF1b+-duct-lining cells to adopt an endocrine cell identity
and that, at least the glucagon+ cells thereby generated, can
subsequently be converted into b-like cells.
To gain further insight into the mechanisms underlying the
insulin+ cell hyperplasia observed in this model, a 10 day bromo-
deoxyuridine (BrdU) pulse-chase was performed. A 5.2-fold
increase in BrdU-labeled cell number was thereby observed
(Figures 4A–4D and S4V). Surprisingly, most BrdU+ cells were
found predominantly localized in the ductal lining (Figures 4B–
4D). Under these conditions, the expression of the develop-
mental proendocrine gene, Ngn3, was investigated. Ngn3 has
previously been found re-expressed in duct-lining cells after
severe injury (Pan et al., 2013; Xu et al., 2008) or constitutive,
ectopic expression of Pax4 (Collombat et al., 2009). Ngn3
expression in adult islet cells was previously reported by
others (Wang et al., 2009), but it appeared extremely weak in
our control mice (Figure S7A) due to a very low expression level.
Nevertheless, in 12-month-old Dox+ Glu-rtTA::TetO-Pax4 mice,
Ngn3 expression was found robustly reactivated within the
ductal lining (Figures 4D, 4G, 4H, and S7B) and, transitorily, in
a subset of islet cells located adjacent to ducts (Figures 4E–
4H). The contribution of Ngn3-re-expressing duct-lining cells
to the islet hypertrophy was determined by lineage tracing in
Glu-rtTA::TetO-Pax4::ROSA26-b-gal mice crossed with Ngn3-
CreER animals (Gu et al., 2002). Although islet cells of Tam-
treated quadruple transgenics or of Ngn3-CreER::Rosa26-
b-gal controls appeared mostly negative for b-galactosidase
(2.3% of endocrine cells labeled after 2 months of Tam
treatment, suggestive of scattered/low expression of Ngn3 in
adult cells; Figures 4I and 4J), 35% ± 7% of periductal cells
were found to be positive for b-galactosidase in Tam+Dox-
treated animals (Figures 4I–4U). Importantly, a similar propor-
tion, 28% ± 7%, of neogenerated endocrine cells appeared
to be b-galactosidase+, with such cells expressing insulin,
glucagon, or somatostatin (Figures 4Q–4T). Hence, Pax4misex-
pression in adult glucagon+ cells leads to their conversion
into b-like cells. Subsequently, our data indicate a transient
re-expression of Ngn3 in duct-lining cells (labeled and tracedvelopmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc. 89
Figure 2. Pax4Misexpression in Adult Glucagon+ Cells Can Be Controlled and Results in Islet Hypertrophy and in the Misallocation of Non-b
Cells within the Islet
(A–F) Not only do 6-month-old 4mDox+ pancreata display a substantial b-like cell hyperplasia (islets outlined in white), an abnormal localization of glucagon+
(A–C), PP (A and D), and d cells (E and F) is also noted, these being mostly detected at a pole of the islet adjacent to neighboring ducts (lumen outlined in yellow)
or within the ductal lining. In subsequent figures, non-b cells may not appear at a pole of the islet because ducts can be located above/below the section: only
a three-dimensional examination allows proper visualization (Movie S2).
(G) To determine whether Pax4 misexpression could be arrested, 1.5-month-old WT and Glu-rtTA::TetO-Pax4 animals were initially treated (or not) with Dox
for 1 month. Subsequently, Dox administration was either discontinued or prolonged for 3 additional months. Examination and islet size quantification were
(legend continued on next page)
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converted into endocrine cells.
Ngn3-Mediated EMT in Adult Dox+ Glu-rtTA::TetO-Pax4
Mice
To gain a deeper insight into the molecular mechanisms under-
lying Pax4-mediated regeneration, transcriptome analyses
were performed on pancreata of Glu-rtTA::TetO-Pax4 mice
that received Dox for increasing periods of time compared to
age-/sex-matched Dox- controls. Interestingly, whereas the
expression of the stem cell marker genes Oct4 and Nanog was
unaltered (Table S3), the expression of Snail2, Vimentin, Ngn3,
and Sox11, transcriptional regulators of the developmental
epithelial-mesenchymal transition (EMT) (Hargrave et al., 1997;
Lioubinski et al., 2003; Rukstalis and Habener, 2007), was
found dramatically increased (Table S3). These results were
confirmed by real-time quantitative PCR (qPCR) (Table S3) and
immunohistochemistry (Figure 5). Indeed, Vimentin, the canoni-
cal mesenchymal marker, was found widely re-expressed in
the cell-dense clusters surrounding ducts (Figures 5A–5F, 5I,
S5, S7C, and S7D). Nestin+ cells were also found in the same
location (Figures 5G and 5H). It is important to note that the
expression of Vimentin is normally absent in this location in
WT/Dox pancreas (Figures 5E and S7C). In fact, further exam-
ination outlined a few E-cadherin+ Vimentin+ duct-lining cells
(Figures 5A–5D); these cells most likely acquired a migratory
phenotype as seen during embryonic EMT. Conversion from
Vimentin+ to insulin+ cells was suggested by the presence of
rare double-positive cells (Figure 5I). Due to technical limitations,
we could not codetect b-gal+ and Vimentin+ cells in Glu-rtTA::
TetO-Pax4::HNF1b-CreER::ROSA26-b-gal pancreata; however,
numerous b-gal+ cells were found within the ductal lining where
most Vimentin+ cells were detected (Figure 5J). Sox11 and
Snail2 also appeared ectopically expressed in cells clustered
around the ductal epithelium of Dox+ Glu-rtTA::TetO-Pax4
pancreata (Figures 5L, 5N, and S7F), in contrast to control
mice (Figures 5K and 5M). Of note, Pan et al. (2013) recently
found that, upon pancreatic duct ligation (PDL), acinar cells
could be converted into duct-like cells ectopically expressing
Ptf1a, a fraction of which being further converted into endocrine
cells. Interestingly, Ptf1a was not detected in ductal cells of
Glu-rtTA::TetO-Pax4 pancreata (Figures S7G and S7H), indi-
cating that acinar cells do not seem to contribute to the neogen-
erated endocrine cell population in our model.
Since Ngn3 can induce the EMT during pancreas morphogen-
esis through the stabilization/activation of Snail2 (Gouzi et al.,
2011), Ngn3 expression was inhibited by knockdown to assess
its role in EMT reinduction and islet overgrowth upon Pax4
misexpression. Glu-rtTA::TetO-Pax4 animals were thereforeperformed at 1.5, 2.5, and 5.5 months of age. Although islet size appears simila
increase is noted at 2.5 months of age solely in Dox-treated mice. Islet size is fo
4 months (in red). Importantly, such reincrease is not seen in 5.5-month-old G
2.5months of age (in pink). An interesting observation is that there is no return to a
b-like cells are maintained even when Pax4 misexpression has been discontinu
found to match the increase in insulin+/Pax4+ cell numbers: a drastic increase is
in animals for which Dox administration was interrupted. The latter still display a s
cell population. n > 3.
All values are depicted as mean ± SEM. ***p < 0.001, **p < 0.01 using ANOVA c
Deinjected with GFP-encoding lentiviruses containing either a
small hairpin RNA (shRNA) targeting Ngn3 or a scrambled
sequence (Collombat et al., 2009; Xu et al., 2008), subsequently
treated with Dox, and examined 3 weeks later. Immunohisto-
chemical analyses using antibodies raised against GFP, CK19,
and synaptophysin confirmed previously published results
(Collombat et al., 2009; Xu et al., 2008) by demonstrating
a targeting of 53% ± 8% of CK19+ ductal cells and of 4% ±
3% of synaptophysin+ endocrine cells (Figure 6C). Similarly,
using qPCR, we noted a 45% ± 9% decrease in Ngn3 transcript
contents in pancreata infected with the lentiviruses containing
shRNAs targeting Ngn3, as compared to scrambled-infected
pancreata (Figure 6C). Both islet size and number were
found significantly decreased in Ngn3 knockdown pancreata
compared to controls (Figures 6A–6C). Similarly, Ngn3+ and
Snail2+ cell contents were also found diminished (Figures 6D
and 6E), suggesting a causative role of Ngn3 in EMT. Interest-
ingly, a similar prevention of islet hypertrophy was noted when
Dox+ Glu-rtTA::TetO-Pax4 animals were treated for 1 month
with exogenous glucagon (Figures 6F–6K), suggesting that
the shortage in the glucagon hormone caused by the Pax4-
mediated glucagon+-to-b-like conversion promotes such b-like
cell neogenesis. Thus, in animals misexpressing Pax4 in adult
glucagon+ cells, our results support the notion of a glucagon
shortage-dependent mobilization of duct-lining cells that re-
express Ngn3 and adopt an endocrine cell identity through
processes involving the reactivation of embryonic EMT. To
our knowledge, this corresponds to the first demonstration of
EMT reactivation in the adult context outside of pathological
conditions.
Controlled Pax4Misexpression in Adult Glucagon+ Cells
Can InduceMultiple Cycles of bCell-Mass Regeneration
The b cell phenotype and glucose responsiveness of Dox+
Glu-rtTA::TetO-Pax4 mice were examined in vivo. In addition
to a normal basal glycemia (Table S1), these animals responded
better to glucose challenges performed at different ages or
after various durations of Dox administration, with a lower peak
in glycemia and a faster normalization (Figure 7A; data not
shown). As expected, circulating insulin levels were found
normal under physiological conditions but dramatically
increased in challenged Dox+ mice compared to controls (Fig-
ure 7A), suggestive of an increased b-like cell mass. However,
upon insulin challenge, the glycemic variations in induced
Glu-rtTA::TetO-Pax4 mice remained similar to that of controls,
indicating an unaltered response to insulin (data not shown).
To determine whether neogenerated insulin+ cells in
Dox+ Glu-rtTA::TetO-Pax4 mice were functional, 4-month-old
1mDox+ Glu-rtTA::TetO-Pax4 mice were injected with a highr in all conditions at the time of Dox induction (1.5 month of age), a significant
und to be further increased in Glu-rtTA::TetO-Pax4 mice treated with Dox for
lu-rtTA::TetO-Pax4 mice for which Dox administration has been stopped at
normal size once Dox treatment is arrested, suggesting that the neo-generated
ed. The amount of Pax4 transcripts, quantified in 5.5-month-old animals, is
noted in 4mDox+ mice (as compared to controls, p < 0.001), which is not seen
lightly elevated Pax4 transcript content reflecting the increased insulin+/Pax4+
omparison. See also Figure S5 and Movie S2.
velopmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc. 91
Figure 3. Upon Pax4Misexpression in Adult a Cells, Glucagon-Expressing Cells and HNF1b+ Duct Cells Can Adopt an Insulin+ Cell Identity
(A–I) Immunofluorescence of pancreata of 6-month-old 4mDox+ Glu-rtTA::TetO-Pax4 mice outlines few cells positive for both insulin and glucagon (A–D),
suggesting a putative glucagon+-to-b-like cell conversion. Glucagon+ cell lineage tracing on 6-month-old 4mDox+Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-b-gal
pancreata shows X-gal staining in a number of cells located within the islet core where insulin+ cells are normally located (E). Immunohistochemistry reveals that
most b-gal+ cells are, in fact, insulin+, indicating a conversion of glucagon+ cells into insulin+ cells (F and G). Smaller islets, most likely newly formed, are found
almost uniformly positive for b-gal (H and I).
(J–U) The detection of cells expressing the ductal marker osteopontin together with insulin (J), glucagon (K), or somatostatin (L) suggests a potential involvement
of duct-lining cells in endocrine cell neogenesis. Importantly, after their outcome using lineage tracing, we demonstrate the conversion of HNF1b+ duct-lining cells
into endocrine cells and more specifically, insulin-producing cells (M–U).
See also Figure S6.
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Figure 4. Assessment of Cell Proliferation and of the Contribution of Ngn3-Re-expressing Cells to the Supplementary Endocrine Cell Pop-
ulation of Induced Glu-rtTA::TetO-Pax4 Mice
(A–H) The detection of proliferating cells in 4-month-old 1mDox+ Glu-rtTA::TetO-Pax4 animals, using a 10 day pulse of BrdU, outlines a 5.2-fold increase in BrdU-
labeled cell numbers (B–D), as compared to their nontreated counterparts (A). Importantly, these are mostly found outside of the islets, in the adjacent ductal
lining. Ngn3 detection reveals a reactivation of this developmental factor in the ductal lining, its expression persisting in a few insulin-labeled cells for a limited
amount of time (D–H).
(I–T) Lineage tracing experiments were undertaken by following the fate of adult Ngn3+ cells in 7.5-month-old 2mDox+/2mTam+ Glu-rtTA::TetO-Pax4::Ngn3-
CreER::ROSA26-b-gal. b-galactosidase activity assayed using X-gal staining and immunohistochemistry is found in very few islet cells of 2mTam+ Ngn3-
CreER::ROSA26-b-gal controls (I and J), but present in Dox+/Tam+ quadruple transgenic islets (K–N and P), ductal lining (O), and a number of insulin+ (K and L,
and Q and R), glucagon+ (S), or somatostatin+ (T) cells, indicating that cells re-expressing Ngn3 eventually adopt an endocrine cell identity.
(U) In fact, quantitative analyses demonstrate a b-gal labeling of35%of duct cells. Importantly,16%of endocrine cells in inducedGlu-rtTA::TetO-Pax4::Ngn3-
CreER::ROSA26-b-gal pancreata also appear to be b-gal+. By factoring in the islet hypertrophy, these are found to represent28% of supplementary endocrine
cells, a percentage in line with the proportion of labeled duct cells. The indicated percentages (±SEM) correspond to quantification of Pax6+ (endocrine cell
quantification) or osteospontin+ (duct cell assessment) cells expressing b-galactosidase using cell counts (every tenth section) on at least three animals per
genotype. For X-gal staining, the counting of b-galactosidase+ cells was reported to the number of islet cells assessed with DAPI staining.
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Figure 5. Reawakening of the EMT in Glu-rtTA::TetO-Pax4 Pancreata
Immunohistochemical analyses reveal that key players of the developmental EMT are re-expressed in Dox+ Glu-rtTA::TetO-Pax4 pancreata. In 6-month-old
3mDox+ animals, the mesenchymal markers Vimentin (A–F and I), Nestin (G and H), Sox11 (K and L), and Snail2 (M and N) are all found re-/ectopically expressed
in the previously noted mesenchyme-like structures that surround a number of ducts (Figure S5). A coexpression of Vimentin and E-cadherin is also observed in
scattered cells (A–D); similarly, a number of cells are found to be positive for both insulin and Vimentin (I): these results suggest a putative transition from an
epithelial to mesenchymal phenotype and, subsequently, from amesenchymal to an endocrine identity. Due to technical limitations, we could not perform b-gal+
and Vimentin+ cell codetection in Glu-rtTA::TetO-Pax4::HNF1b-CreER::ROSA26-b-gal pancreata. Despite this issue, numerous b-gal+ cells were found located in
the ductal lining (J) wheremost Vimentin+ cells are observed, supporting the notion that duct-lining cells pass through a Vimentin-expressing cell stage/EMT cycle
prior to the acquisition of an endocrine cell identity. Note that, due to the strength of E-cadherin labeling in ducts, the overall brightness of E-cadherin staining was
digitally diminished to allow for a clearer visualization. In selected photographs, islets are outlined in white dashed lines whereas the ductal lumen is outlined in
yellow dashed lines. See also Figure S7.
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producing cells (Mansford and Opie, 1968). Although control
mice quickly became diabetic and died from massive hypergly-
cemia, all Dox+ Glu-rtTA::TetO-Pax4 mice displayed a short
period of hyperglycemia but then steadily restored normoglyce-
mia and survived (Figures 7B and 7C). Immunohistochemical
analysis at different time points demonstrated that insulin+ cells
were progressively regenerated after b cell loss (Figure 7D). Of
note, in pancreata of 1mDox+ Glu-rtTA::TetO-Pax4::Glu-Cre::94 Developmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc.ROSA26-b-gal animals treated with STZ and examined
2 months later, the majority of insulin+ cells were found to
be b-galactosidase+ (Figure 7E), further documenting that
numerous newly generated b-like cells were derived from
glucagon-expressing cells.
The surviving mice were then maintained on Dox for 1 month,
and, subsequently, Dox treatment was either discontinued or
prolonged. Five weeks later, another glucose challenge showed
that solely the mice that were maintained on Dox during the
Figure 6. Ngn3 Knockdown or Glucagon Supplementation Prevents EMT-Driven Islet Hyperplasia/Neogenesis
(A–E) Infection of 3-month-old Glu-rtTA::TetO-Pax4 animals using GFP-encoding lentiviruses producing either a shRNA targeting Ngn3 transcripts or a
scrambled shRNA. After infection, the animals were administered Dox for 3 weeks and sacrificed for examination: Ngn3 knockdown pancreata exhibit a
45% decrease in Ngn3 transcript content (C), but also a significant 38% diminution in insulin+ cell counts and a 39% decrease in islet numbers, as compared to
their scramble-infected counterparts (A–C). A drastic reduction in Snail2-re-expressing cells is also noted in knockdown animals (D–E). For a better overview,
photographs in (A) and (B) correspond to a composite regrouping 64 pictures.
(F–K) Examination of 5-month-old Glu-rtTA::TetO-Pax4 animals, injected with either a saline solution or glucagon, and concomitantly treated with Dox for
3 months. Although their glycemia was found within normal ranges (data not shown), note the diminished size (F, J, and K) and number of islets (G, J, and K),
as well as decreased insulin- (H, J, and K), and glucagon- (I) producing cell counts in animals supplemented with glucagon as compared to genotype-matched
Dox-treated animals injected with saline. n > 3. All values are depicted as mean ± SEM. **p < 0.01, *p < 0.05 using ANOVA comparison.
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Figure 7. The Whole b Cell Mass Can Be Replenished Repeatedly in Dox-Treated Glu-rtTA::TetO-Pax4 Animals
(A) Three-month-old 1mDox Glu-rtTA::TetO-Pax4 (and controls corresponding to WT/Dox age-/sex-matched animals) were challenged with glucose. Induced
animals perform better than controls with a lower peak in glycemia and a faster return to euglycemia, suggestive of an increased b-like cell mass as outlined by
circulating insulin measurements.
(B–E) One month after Dox administration, mice were subjected to streptozotocin treatment. Their glycemia (B), survival (C), and pancreatic islet composition (D)
weremonitored. After a peak in glycemia, a steady recovery is noted for inducedmice (B), whereas controls die frommassive hyperglycemia (C). Such recovery is
associatedwith a clear regeneration of their b cell massmonitored 5, 10, 30, and 80 days poststreptozotocin administration (D). The same experiments performed
in Glu-rtTA::TetO-Pax4::Glu-Cre::Rosa26-b-gal animals reveals that most regenerated b-like cells derive from cells that expressed the glucagon hormone (E).
(F–H) At 5 months of age, Dox administration was either discontinued or prolonged for the surviving animals. Four weeks later, another glucose challenge was
initiated and yet again, Dox-treated animals performed better than controls (F). Interestingly, Glu-rtTA::TetO-Pax4 animals for which Dox administration has been
arrested react in a similar fashion to controls. Subsequently, these ‘‘survivors’’ were reinjected with streptozotocin resulting in Dox-treated mice seeing another
increase in their glycemia followed by a progressive return to normal ranges whereas all controls died displaying a massive hyperglycemia (G and H). Importantly,
animals for which Dox treatment has been stopped also died presenting a massive increase in blood glucose levels (G and H).
(I) In addition, a third streptozotocin treatment leads to the same outcome, indicating that the b cell mass can be replaced at least three times.
For all experiments, n > 3; all values are depicted as mean ± SEM. ***p < 0.001, **p < 0.01 using ANOVA comparison (A, B, and F). (C and H) Kaplan-Meier survival
curve with ***p < 0.001 by log-rank test.
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When these mice were subjected to another round of STZ, again
only those that were kept on Dox during the whole process sur-
vived and showed a progressive normalization of their glycemia
(Figures 7G and 7H). This indicates that the newly formed b-like
cells are sensitive to STZ but also that a second cycle of b-like
cell regeneration can be induced (data similar to Figure 7D). In
contrast, mice with discontinued Dox supply died of hyperglyce-
mia (Figures 7G and 7H). To further test the robust capacity of
this regeneration process, a third dose of STZ was administered
to the survivingmice and resulted in a similar outcome (Figure 7I).96 Developmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc.The latter animals survived more than 7 months after the third in-
jection of STZ (data not shown). These results provide evidence
(1) that Pax4 is instrumental to glucagon+ cell-mediated b-like
cell regeneration, (2) that the newly formed b-like cells are func-
tional and can counter chemically induced diabetes, and (3) that
the functional b cell mass can be repetitively replenished.
DISCUSSION
Our study demonstrates that the misexpression of Pax4 in
adult a cells promotes their conversion into b-like cells, but
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crease in islet size and number. Importantly, these processes
can be regulated and depend on the duration ofPax4misexpres-
sion, but not on the age of induction. After the initial conversion
of a cells into b-like cells, increased proliferation and ectopic
expression of Ngn3 are noted in the ductal lining, a subset of
duct-lining/Ngn3-re-expressing cells eventually adopting a
glucagon+ cell identity and, subsequently, a b-like cell pheno-
type. Further analyses demonstrate that such endocrine cell
neogenesis involves a Ngn3-mediated reactivation of the
developmental EMT. Last, we provide evidence that Pax4
misexpression in adult glucagon+ cells is able to promote
several cycles of replenishment of the b-like cell mass, and
thereby to reverse several rounds of toxin-induced diabetes.
Pax4 Promotes Glucagon+ Cell-Mediated b-like Cell
Neogenesis
Our analysis indicates that, upon Pax4 misexpression, adult
a cells can be converted into cells displaying most features of
true b cells independently of their age, maturation state, and
microenvironment. Subsequently, the consistent detection of
glucagon+ cells combined to lineage-tracing experiments show
a cycle of glucagon+ cell neogenesis and conversion into b-like
cells, resulting in a limited increase in islet number and in a pro-
gressive, continuous, and controllable b-like cell hyperplasia.
Interestingly, the continuous generation of b-like cells observed
in these animals suggests an inherent capability of the adult
pancreas to generate glucagon-producing cells in great
numbers, these being turned into b-like cells upon Pax4 misex-
pression and islets reaching up to ten times the size of control
islets. As important was the observation of a limited increase in
the number of islets: understanding the mechanisms involved
in this islet neogenesis, but also in its restriction, would be of
interest for diabetes research.
Concomitantly to b-like cell neogenesis, an increase in the
number of proliferating cells is noted in the ductal epithelium/
lining where Ngn3 expression is reactivated. These results are
in agreement with previous reports suggesting that, under spe-
cific conditions, facultative precursor cells may be induced to
re-express Ngn3 and eventually adopt an endocrine cell pheno-
type (Collombat et al., 2009; Pan and Wright, 2011; Xu et al.,
2008). Of interest was the recent detection of low levels of
Ngn3 expression in adult endocrine cells but not in the ductal
compartment (Wang et al., 2009). Under our experimental condi-
tions, whereas we detected very low expression levels of Ngn3 in
control islets by immunohistochemistry, a robust re-expression
was noted in duct-lining cells of Dox+ Glu-rtTA::TetO-Pax4
mouse pancreas. Lineage-tracing experiments indicated that a
number of adult Ngn3+ or HNF1b+ duct-lining cells could eventu-
ally adopt a b-like cell identity. Interestingly, combining these
quantitative analyses with glucagon+ cell lineage tracing, our
data suggest that: (1) the large proportion of labeled glucagon+
cells matched the proportion of newly formed marked b-like
cells, suggesting that, upon initial a-to-b-like cell conversion,
glucagon+ cells are regenerated and further converted into
b-like cells as long as Pax4 is misexpressed; (2) the proportion
of labeled Ngn3+ or HNF1b+ cells also nearly matched the pro-
portion of marked newly formed b-like cells, indicating that a
majority of these b-like cells derived from Ngn3 re-expressingDeor HNF1b-labeled cells. However, due to the incomplete labeling
of these different cell subtypes (inherent to lineage tracing ap-
proaches), one cannot exclude that a fraction of neo-generated
b-like cells could have an alternative origin. A possibility could be
an acinar origin: indeed, a recent report from Pan et al. (2013)
suggests that, upon PDL, Ptf1a+ acinar cells could adopt a
Ptf1a+ HNF1b+ ductal cell identity, re-express Ngn3, and be
further converted into endocrine cells. However, in Pax4-misex-
pressing animals, Ptf1a was not found ectopically produced in
ductal or endocrine cells, and no evidence of acinar-to-duct or
acinar-to-endocrine cell conversion was noted, suggesting that
two different mechanisms operate. A likely explanation could
lie in the differences between the approaches used. Indeed,
with PDL corresponding to a fairly drasticmodel of acute pancre-
atitis involving massive inflammation and cell death, it is there-
fore conceivable that additional/facultative cell-replacement
mechanisms are activated as compared to Pax4-misexpressing
animals, which are mostly characterized by a glucagon+-to-
b-like cell conversion. Thus, our data demonstrate that Pax4
misexpression can single-handedly promote several cycles of
regeneration of the b cell mass without requiring PDL. Addition-
ally, these results also suggest that Ngn3+ or HNF1b+ cells are
initially converted into glucagon+ cells and subsequently into
b-like cells. The key role exerted by Ngn3 in these processes
was further confirmed in knockdown experiments showing a
strongly diminished b-like cell hyperplasia.
Our analyses indicate a recapitulation of the Ngn3-mediated
endocrine developmental program in this specific model of
Pax4 misexpression in adult glucagon+ cells. However, unlike
during pancreas morphogenesis, the proportion of the gener-
ated endocrine cell subtypes is clearly in favor of the glucagon+
cell lineage. One likely explanation could be the glucagon deple-
tion provoked by the glucagon+-to-b-cell conversion. Indeed,
it was previously found that alterations in glucagon signaling
or glucagon shortage could trigger an a-like cell neogenesis
(Furuta et al., 1997; Gelling et al., 2003; Longuet et al., 2013).
It is conceivable that, in the present case, a similar a-like cell
hyperplasia is induced, such cells subsequently misexpressing
Pax4 and being turned into b-like cells. The decreased b-like
cell hyperplasia observed after glucagon supplementation sup-
ports this notion. It should be noted that, in Pax4-misexpressing
animals, the neo-generated glucagon+ cells detected prior to
their conversion into b-like cells display a mature PC1/3-/GLP-
1R a-like cell phenotype (and thereby not a pro-a cell identity).
However, due to the lack of well-characterized marker genes
and in the absence of a more in-depth analysis, one cannot
ascertain that these correspond to true a cells.
Although the glucagon+ cell lineage is clearly favored in these
regeneration processes, a few somatostatin+ or PP+ cells were
also detected. However, technical limitations (lack of appro-
priate CreER mouse lines) prevented the tracing of their lineage.
Given the systematic polarity of their distribution within islets
and the fact that their number does not increase over time, it is
conceivable that such cells correspond to Ngn3-derived cells
(as demonstrated using lineage tracing) that have escaped the
a-cell-lineage favoring. One could also postulate that such cells
could also acquire a b-like cell identity. However, the definitive
validation of this postulate will require the generation of proper
mouse lines.velopmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc. 97
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Pancreas
The exploration of the molecular mechanisms underlying these
endocrine cell regeneration processes outlined a Ngn3-medi-
ated reawakening of the developmental EMT (Chiang and
Melton, 2003; Cole et al., 2009; Gouzi et al., 2011; Rukstalis
and Habener, 2007). Indeed, besides Ngn3 re-expression, the
ectopic expression of epithelial/mesenchymal markers, such
as Vimentin, Nestin, Snail2, and Sox11, is noted in our adult
mice, with the knockdown of Ngn3 preventing their reactivation.
Of note, the acquisition of a mesenchymal, migratory
phenotype implies the subsequent and opposite conversion of
mesenchyme-like cells to epithelial/endocrine ones. Despite an
apparently rapid transition, we did indeed observe a few cells
expressing Vimentin and insulin/glucagon. Together, our results
thus support the concept that precursor cells localized in the
ductal lining are mobilized and re-expressNgn3 prior to embark-
ing on the EMT pathway leading to endocrine cell genesis and,
at least, glucagon+-to-b-like cell conversion (see model in Fig-
ure S7I). Whether all neo-generated islet cells pass through
this cycle or whether a subset of duct-derived cells can expand
prior to hormone expression or transactivate the dedifferen-
tiation/proliferation/redifferentiation of endogenous islet cells
remains to be determined.Age-Independent Reversion of Several Rounds
of Toxin-Induced Diabetes
In Dox-treated Glu-rtTA::TetO-Pax4 animals, hyperplastic
insulin+ cells display a b cell phenotype and are fully functional
upon challenge. Interestingly, the newly formed b-like cells can
repopulate the islets of STZ-treated animals and restore
euglycemia. Importantly, these regenerative processes were
responsive to at least two additional rounds of STZ injections.
The capacity to repeatedly activate duct-to-b-like cell regenera-
tionmay therefore offer new therapeutic strategies for type 1, but
also type 2, diabetes where putatively regenerated b-like cells
could, with time, be killed by the immune system. Taken
together, our data indicate that (1) Pax4 misexpression is both
necessary and sufficient for b-like cell neogenesis, (2) the newly
formed b-like cells are functional, (3) Pax4 expression can be
regulated, (4) the complete b cell mass can be replaced at least
three times, and (5) that several cycles of glucagon+ cell-medi-
ated b-like cell regeneration can be successfully triggered in an
age-independent manner. Based on these findings, we suggest
that strategies controlling the expression of Pax4, Ngn3, or EMT
induction, or of their molecular targets/cofactors, may pave
new avenues for the treatment of diabetes.EXPERIMENTAL PROCEDURES
Mouse Manipulations
The strategy used to generate the Glu-rtTA::TetO-Pax4 mouse line is depicted
in Figures S1A and S1B and detailed in the corresponding figure legends.
These mice were also crossed with the Glucagon-Cre (Herrera, 2000), Ngn3-
CreER (Gu et al., 2002), HNF-CreER (Gu et al., 2002), TetO-Cre (Perl et al.,
2002), and/or ROSA-b-gal (Soriano, 1999) mouse lines. Doxycycline (Sigma)
was administered via the drinking water prepared freshly once a week at
a concentration of 2 g/l. Tamoxifen (Sigma) was administered by gavage
at a concentration of 20 mg/ml. To assess the cellular proliferation upon
doxycycline-mediated induction of Pax4, Glu-rtTA::TetO-Pax4 mice were98 Developmental Cell 26, 86–100, July 15, 2013 ª2013 Elsevier Inc.treated with doxycycline and subsequently with BrdU (in drinking water) for
10 days prior to examination (1 mg/ml solution). To assess the effects of
glucagon on islet size, mice were injected intraperitoneally twice daily (every
12 hr) with 6 mg of glucagon (Sigma) and sacrificed after 3 weeks of treatment.
Last, lentivirus production and injection were performed as previously
described (Xu et al., 2008, Collombat et al., 2009). All animal experiments
were validated by our local ethical committees.
Immunohistochemistry
Tissues were fixed for 30 min in 4% paraformaldehyde at 4C and embedded
in paraffin, and 8 mm sections were applied to slides. These sections were
assayed as previously described (Collombat et al., 2003) using DAPI or propi-
dium iodine as counterstain. The primary antibodies used were the following:
mouse monoclonal anti-insulin (1/500; Sigma), anti-glucagon (1/500; Sigma),
anti-E-cadherin (1/200; BD Transduction Lab), anti-Nestin (1/1,000; Millipore),
and anti-SNAI2 (1/100; Santa Cruz Biotechnology); guinea pig anti-insulin
(1/500; Linco), anti-glucagon (1/500; Millipore); rat monoclonal anti-somato-
statin (1/250; Chemical International); mouse anti-Ngn3 (1/10,000; Novo
Nordisk), anti-BrdU (1/40; Roche); rabbit anti-Nkx6.1 (1/3,000; Novo Nordisk),
anti-Pax4 (1/4,000 kindly provided by B. Sosa-Pineda), anti-Arx (1/500), anti-
Pdx1 (1/1,000; kindly provided by C. Wright), anti-NeuroD1 (1/500; Millipore),
anti-MafA (1/500; Abcam), anti-PC1/3 (1/500; Milipore), anti-Sox11 (1/200;
Santa Cruz), anti-GLP1R (1/1,000; kindly provided by J. Habener) and anti-
Glut2 (1/5,000; Chemical International); goat anti-osteopontin (1/100; R&D
Systems); and anti-Vimentin (1/50; Santa Cruz). The secondary antibodies
(1/1,000; Molecular Probes) used were Alexa Fluor 594 and 488 anti-mouse;
Alexa Fluor 594 and 488 anti-rabbit; Alexa Fluor 594 and 488 anti-guinea
pig; Alexa Fluor 594 and 488 anti-goat. Pictures were processed using ZEISS
Axioimager Z1 and LEICA DM 6000 B. For quantification purposes, stained
cells were counted manually on every tenth section.
b-Galactosidase-Based Lineage-Tracing Experiments
Pancreatic tissues were isolated and fixed for 30 min at 4C in a solution con-
taining 1% formaldehyde, 0.2% glutaraldehyde, and 0.02%NP40. The tissues
were dehydrated in 25% sucrose overnight at 4C. Prior to sectioning, tissues
were embedded in freezing medium. For b-galactosidase activity assessment,
the tissues were washed in PBS and then incubated overnight in staining
solution (500 mM K3Fe[CN]6, 250 mM K4Fe[CN]6, 0.5 M MgCl2, 40 mg/ml
X-gal in dimethylformamide).
Cell Counts
Quantitative analyses were performed by counting of colored pixels on
(immuno-) stained sections of pancreas using the Photoshop software.
Specifically, every tenth section was processed using the same settings for
all animals and genotypes.
Challenges and Blood Glucose Level Measurement
For challenge purposes, animals were fasted for 16 hr and injected intra-
peritoneally with glucose (2 g/kg of bodyweight) or insulin (0.75 U/kg). Blood
glucose levels were measured at the indicated time points postinjection with
a ONETOUCH Vita glucometer (Life Scan).
Induction of Streptozotocin-Mediated Diabetes
To induce hyperglycemia, STZ (Sigma) was dissolved in 0.1 M sodium
citrate buffer (pH 4.5), and a single dose was administered intraperitoneally
(100–200 mg/kg) within 10 min of dissolution. Diabetes progression was
assessed by monitoring the blood glucose levels and/or survival rates of mice.
Data Analysis
All values are depicted as mean ± SEM and considered significant if p < 0.05.
Data were statistically analyzed by ANOVA.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, three tables, and two movies and can be found with this
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